Nanoparticles for imaging: Top or flop?

Radiology

Volumn 273, Issue 1, 2014, Pages 10-28

  Kiessling, Fabian ^a   Mertens, Marianne E ^a   Grimm, Jan ^b   Lammers, Twan ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIAL; CONTRAST MEDIUM; NANOPARTICLE;

CHEMISTRY; DIAGNOSTIC IMAGING; DIAGNOSTIC USE; HUMAN;

BIOCOMPATIBLE MATERIALS; CONTRAST MEDIA; DIAGNOSTIC IMAGING; HUMANS; NANOPARTICLES;

EID: 84908569662     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.14131520     Document Type: Review

References (157)

1. Yigit MV, Moore A, Medarova Z. Magnetic nanoparticles for cancer diagnosis and therapy. Pharm Res 2012; 29 (5) : 1180-1188.
2. Jakhmola A, Anton N, Vandamme TF. Inorganic nanoparticles based contrast agents for x-ray computed tomography. Adv Healthc Mater 2012; 1 (4) : 413-431.
3. Wahajuddin AS, Arora S. Superparamagnetic iron oxide nanoparticles: Magnetic nanoplatforms as drug carriers. Int J Nanomedicine 2012; 7: 3445-3471.
4. Kiessling F, Morgenstern B, Zhang C. Contrast agents and applications to assess tumor angiogenesis in vivo by magnetic resonance imaging. Curr Med Chem 2007; 14 (1) : 77-91.
5. Liu Z, Kiessling F, Gaetjens J. Advanced nanomaterials in multimodal imaging: Design, functionalization, and biomedical applications. J Nanomater 2010; 894303.
6. Heneweer C, Gendy SE, Peñate-Medina O. Liposomes and inorganic nanoparticles for drug delivery and cancer imaging. Ther Deliv 2012; 3 (5) : 645-656.
7. Duncan R, Gaspar R. Nanomedicine (s) under the microscope. Mol Pharm 2011; 8 (6) : 2101-2141.
8. Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. Theranostic nanomedicine. Acc Chem Res 2011; 44 (10) : 1029-1038.
9. Rizzo LY, Theek B, Storm G, Kiessling F, Lammers T. Recent progress in nanomedicine: Therapeutic, diagnostic and theranostic applications. Curr Opin Biotechnol 2013; 24 (6) : 1159-1166.
10. Grimm J, Scheinberg DA. Will nanotechnology influence targeted cancer therapy? Semin Radiat Oncol 2011; 21 (2) : 80-87.
11. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46 (12 Pt 1) : 6387-6392.
12. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010; 7 (11) : 653-664.
13. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. J Control Release 2012; 161 (2) : 175-187.
14. Wagner M, Wagner S, Schnorr J, et al. Coronary MR angiography using citratecoated very small superparamagnetic iron oxide particles as blood-pool contrast agent: Initial experience in humans. J Magn Reson Imaging 2011; 34 (4) : 816-823.
15. Wheaton AJ, Miyazaki M. Non-contrast enhanced MR angiography: Physical principles. J Magn Reson Imaging 2012; 36 (2) : 286-304.
16. Caravan P. Protein-Targeted gadoliniumbased magnetic resonance imaging (MRI) contrast agents: Design and mechanism of action. Acc Chem Res 2009; 42 (7) : 851-862.
17. Turetschek K, Preda A, Novikov V, et al. Tumor microvascular changes in antiangiogenic treatment: Assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging 2004; 20 (1) : 138-144.
18. Persigehl T, Wall A, Kellert J, et al. Tumor blood volume determination by using susceptibility-corrected DR2∗ multiecho MR. Radiology 2010; 255 (3) : 781-789.
19. Persigehl T, Bieker R, Matuszewski L, et al. Antiangiogenic tumor treatment: Early noninvasive monitoring with USPIO-enhanced MR imaging in mice. Radiology 2007; 244 (2) : 449-456.
20. Pannetier N, Lemasson B, Christen T, et al. Vessel size index measurements in a rat model of glioma: Comparison of the dynamic (Gd) and steady-state (iron-oxide) susceptibility contrast MRI approaches. NMR Biomed 2012; 25 (2) : 218-226.
21. Zwick S, Strecker R, Kiselev V, et al. Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging. J Magn Reson Imaging 2009; 29 (5) : 1125-1133.
22. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: Physicochemical characteristics and applications in MR imaging. Eur Radiol 2001; 11 (11) : 2319-2331.
23. Leike J, Sachse A, Ehritt C, Krause W. Biodistribution and CT-imaging characteristics of iopromide-carrying liposomes in rats. J Liposome Res 1996; 6 (4) : 665-680.
24. Desser TS, Rubin DL, Muller H, McIntire GL, Bacon ER, Toner JL. Blood pool and liver enhancement in CT with liposomal iodixanol: Comparison with iohexol. Acad Radiol 1999; 6 (3) : 176-183.
25. Krause W, Leike J, Sachse A, Schuhmann-Giampieri G. Characterization of iopromide liposomes. Invest Radiol 1993; 28 (11) : 1028-1032.
26. Hallouard F, Anton N, Choquet P, Constantinesco A, Vandamme T. Iodinated blood pool contrast media for preclinical x-ray imaging applications: A review. Biomaterials 2010; 31 (24) : 6249-6268.
27. Kong WH, Lee WJ, Cui ZY, et al. Nanoparticulate carrier containing water-insoluble iodinated oil as a multifunctional contrast agent for computed tomography imaging. Biomaterials 2007; 28 (36) : 5555-5561.
28. Aviv H, Bartling S, Kieslling F, Margel S. Radiopaque iodinated copolymeric nanoparticles for x-ray imaging applications. Biomaterials 2009; 30 (29) : 5610-5616.
29. De Vries A, Custers E, Lub J, van den Bosch S, Nicolay K, Grüll H. Block-copolymer-stabilized iodinated emulsions for use as CT contrast agents. Biomaterials 2010; 31 (25) : 6537-6544.
30. Torchilin VP, Frank-Kamenetsky MD, Wolf GL. CT visualization of blood pool in rats by using long-circulating, iodine-containing micelles. Acad Radiol 1999; 6 (1) : 61-65.
31. Rabin O, Manuel Perez J, Grimm J, Wojtkiewicz G, Weissleder R. An x-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nat Mater 2006; 5 (2) : 118-122.
32. Aviv H, Bartling S, Grinberg I, Margel S. Synthesis and characterization of Bi2O3/HSA core-shell nanoparticles for x-ray imaging applications. J Biomed Mater Res B Appl Biomater 2013; 101 (1) : 131-138.
33. Liu Y, Ai K, Liu J, Yuan Q, He Y, Lu L. Hybrid BaYbF (5) nanoparticles: Novel binary contrast agent for high-resolution in vivo x-ray computed tomography angiography. Adv Healthc Mater 2012; 1 (4) : 461-466.
34. Wilson SR, Burns PN. Microbubble-enhanced US in body imaging: What role? Radiology 2010; 257 (1) : 24-39.
35. Kim YK, Kwak HS, Kim CS, Chung GH, Han YM, Lee JM. Hepatocellular carcinoma in patients with chronic liver disease: Comparison of SPIO-enhanced MR imaging and 16-detector row CT. Radiology 2006; 238 (2) : 531-541.
36. Mack MG, Balzer JO, Straub R, Eichler K, Vogl TJ. Superparamagnetic iron oxide-enhanced MR imaging of head and neck lymph nodes. Radiology 2002; 222 (1) : 239-244.
37. Schmitz SA, Taupitz M, Wagner S, Wolf KJ, Beyersdorff D, Hamm B. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles. J Magn Reson Imaging 2001; 14 (4) : 355-361.
38. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348 (25) : 2491-2499.
39. Saleh A, Wiedermann D, Schroeter M, Jonkmanns C, Jander S, Hoehn M. Central nervous system inflammatory response after cerebral infarction as detected by magnetic resonance imaging. NMR Biomed 2004; 17 (4) : 163-169.
40. Heesakkers RA, Jager GJ, Hövels AM, et al. Prostate cancer: Detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging. Radiology 2009; 251 (2) : 408-414.
41. 99mTclabeled superparamagnetic iron oxide nanoparticles for multimodality SPECT/MRI of sentinel lymph nodes. J Nucl Med 2012; 53 (3) : 459-463.
42. 99mTc-labelled gold nanoparticles capped with HYNIC-peptide/mannose for sentinel lymph node detection. Nucl Med Biol 2011; 38 (1) : 1-11.
43. Kim S, Lim YT, Soltesz EG, et al. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol 2004; 22 (1) : 93-97.
44. Cai X, Li W, Kim CH, Yuan Y, Wang LV, Xia Y. In vivo quantitative evaluation of the transport kinetics of gold nanocages in a lymphatic system by noninvasive photoacoustic tomography. ACS Nano 2011; 5 (12) : 9658-9667.
45. Sever AR, Mills P, Weeks J, et al. Preoperative needle biopsy of sentinel lymph nodes using intradermal microbubbles and contrast-enhanced ultrasound in patients with breast cancer. AJR Am J Roentgenol 2012; 199 (2) : 465-470.
46. Sever AR, Mills P, Jones SE, et al. Preoperative sentinel node identification with ultrasound using microbubbles in patients with breast cancer. AJR Am J Roentgenol 2011; 196 (2) : 251-256.
47. Morana G, Salviato E, Guarise A. Contrast agents for hepatic MRI. Cancer Imaging 2007; 7 (Spec No A) : S24-S27.
48. Weissleder R, Elizondo G, Stark DD, et al. The diagnosis of splenic lymphoma by MR imaging: Value of superparamagnetic iron oxide. AJR Am J Roentgenol 1989; 152 (1) : 175-180.
49. Weissleder R. Liver MR imaging with iron oxides: Toward consensus and clinical practice. Radiology 1994; 193 (3) : 593-595.
50. Rappeport ED, Loft A, Berthelsen AK, et al. Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: A prospective study with intraoperative confirmation. Acta Radiol 2007; 48 (4) : 369-378.
51. Ward J, Guthrie JA, Wilson D, et al. Colorectal hepatic metastases: Detection with SPIO-enhanced breath-hold MR imaging-comparison of optimized sequences. Radiology 2003; 228 (3) : 709-718.
52. Yamamoto H, Yamashita Y, Yoshimatsu S, Baba Y, Takahashi M. MR enhancement of hepatoma by superparamagnetic iron oxide (SPIO) particles. J Comput Assist Tomogr 1995; 19 (4) : 665-667.
53. Reimer P, Tombach B. Hepatic MRI with SPIO: Detection and characterization of focal liver lesions. Eur Radiol 1998; 8 (7) : 1198-1204.
54. Grandin C, Van Beers BE, Robert A, Gigot JF, Geubel A, Pringot J. Benign hepatocellular tumors: MRI after superparamagnetic iron oxide administration. J Comput Assist Tomogr 1995; 19 (3) : 412-418.
55. Wunderbaldinger P, Josephson L, Bremer C, Moore A, Weissleder R. Detection of lymph node metastases by contrast-enhanced MRI in an experimental model. Magn Reson Med 2002; 47 (2) : 292-297.
56. Ross RW, Zietman AL, Xie W, et al. Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Clin Imaging 2009; 33 (4) : 301-305.
57. Pandharipande PV, Harisinghani MG, Ozanne EM, et al. Staging MR lymphangiography of the axilla for early breast cancer: Cost-effectiveness analysis. AJR Am J Roentgenol 2008; 191 (5) : 1308-1319.
58. Guimaraes AR, Tabatabei S, Dahl D, Mc-Dougal WS, Weissleder R, Harisinghani MG. Pilot study evaluating use of lymphotrophic nanoparticle-enhanced magnetic resonance imaging for assessing lymph nodes in renal cell cancer. Urology 2008; 71 (4) : 708-712.
59. Majmudar MD, Yoo J, Keliher EJ, et al. Polymeric nanoparticle PET/MR imaging allows macrophage detection in atherosclerotic plaques. Circ Res 2013; 112 (5) : 755-761.
60. Settles M, Etzrodt M, Kosanke K, et al. Different capacity of monocyte subsets to phagocytose iron-oxide nanoparticles. PLoS ONE 2011; 6 (10) : E25197.
61. Ye Q, Yang D, Williams M, et al. In vivo detection of acute rat renal allograft rejection by MRI with USPIO particles. Kidney Int 2002; 61 (3) : 1124-1135.
62. Yilmaz A, Dengler MA, van der Kuip H, et al. Imaging of myocardial infarction using ultrasmall superparamagnetic iron oxide nanoparticles: A human study using a multi-parametric cardiovascular magnetic resonance imaging approach. Eur Heart J 2013; 34 (6) : 462-475.
63. Denis MC, Mahmood U, Benoist C, Mathis D, Weissleder R. Imaging inflammation of the pancreatic islets in type 1 diabetes. Proc Natl Acad Sci U S A 2004; 101 (34) : 12634-12639.
64. Gaglia JL, Guimaraes AR, Harisinghani M, et al. Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. J Clin Invest 2011; 121 (1) : 442-445.
65. Kircher MF, Gambhir SS, Grimm J. Noninvasive cell-Tracking methods. Nat Rev Clin Oncol 2011; 8 (11) : 677-688.
66. Alam SR, Shah AS, Richards J, et al. Ultrasmall superparamagnetic particles of iron oxide in patients with acute myocardial infarction: Early clinical experience. Circ Cardiovasc Imaging 2012; 5 (5) : 559-565.
67. Sosnovik DE, Nahrendorf M. Cells and iron oxide nanoparticles on the move: Magnetic resonance imaging of monocyte homing and myocardial inflammation in patients with ST-elevation myocardial infarction. Circ Cardiovasc Imaging 2012; 5 (5) : 551-554.
68. Weissleder R, Moore A, Mahmood U, et al. In vivo magnetic resonance imaging of transgene expression. Nat Med 2000; 6 (3) : 351-355.
69. Tannous BA, Grimm J, Perry KF, Chen JW, Weissleder R, Breakefield XO. Metabolic biotinylation of cell surface receptors for in vivo imaging. Nat Methods 2006; 3 (5) : 391-396.
70. Kircher MF, Allport JR, Graves EE, et al. In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res 2003; 63 (20) : 6838-6846.
71. Pittet MJ, Grimm J, Berger CR, et al. In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. Proc Natl Acad Sci U S A 2007; 104 (30) : 12457-12461.
72. Zhou R, Thomas DH, Qiao H, et al. In vivo detection of stem cells grafted in infarcted rat myocardium. J Nucl Med 2005; 46 (5) : 816-822.
73. Grimm J, Swirski FK, Pittet M, Josephson L, Weissleder R. A nanoparticle-based cell labeling agent for cell tracking with SPECT/CT. Mol Imaging 2006; 5 (Suppl 3) : 364.
74. Astolfo A, Schültke E, Menk RH, et al. In vivo visualization of gold-loaded cells in mice using x-ray computed tomography. Nanomedicine (Lond Print) 2013; 9 (2) : 284-292.
75. Gilad AA, Walczak P, McMahon MT, et al. MR tracking of transplanted cells with "positive contrast" using manganese oxide nanoparticles. Magn Reson Med 2008; 60 (1) : 1-7.
76. Pala A, Liberatore M, D'Elia P, et al. Labelling of granulocytes by phagocytic engulfment with 64Cu-labelled chitosan-coated magnetic nanoparticles. Mol Imaging Biol 2012; 14 (5) : 593-598.
77. Zelivyanskaya ML, Nelson JA, Poluektova L, et al. Tracking superparamagnetic iron oxide labeled monocytes in brain by highfield magnetic resonance imaging. J Neurosci Res 2003; 73 (3) : 284-295.
78. Sipe JC, Filippi M, Martino G, et al. Method for intracellular magnetic labeling of human mononuclear cells using approved iron contrast agents. Magn Reson Imaging 1999; 17 (10) : 1521-1523.
79. De Vries IJ, Lesterhuis WJ, Barentsz JO, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 2005; 23 (11) : 1407-1413.
80. Saudek F, Jirák D, Girman P, et al. Magnetic resonance imaging of pancreatic islets transplanted into the liver in humans. Transplantation 2010; 90 (12) : 1602-1606.
81. Tracking inflammatory cells using superparamagnetic particles of iron oxide (spio) and magnetic resonance imaging (MRI). http://clinicaltrials.gov/show/NCT01169935. Updated February 4, 2013. Accessed July 2013.
82. Bulte JW. In vivo MRI cell tracking: Clinical studies. AJR Am J Roentgenol 2009; 193 (2) : 314-325.
83. Zhu J, Zhou L, XingWu F. Tracking neural stem cells in patients with brain trauma. N Engl J Med 2006; 355 (22) : 2376-2378.
84. Callera F, De Melo CMTP. Magnetic resonance tracking of magnetically labeled autologous bone marrow CD34+ cells transplanted into the spinal cord via lumbar puncture technique in patients with chronic spinal cord injury: CD34+ cells' migration into the injured site. Stem Cells Dev 2007; 16 (3) : 461-466.
85. Place ES, Evans ND, Stevens MM. Complexity in biomaterials for tissue engineering. Nat Mater 2009; 8 (6) : 457-470.
86. Kuehnert N, Kraemer NA, Otto J, et al. In vivo MRI visualization of mesh shrinkage using surgical implants loaded with superparamagnetic iron oxides. Surg Endosc 2012; 26 (5) : 1468-1475.
87. Nelson GN, Roh JD, Mirensky TL, et al. Initial evaluation of the use of USPIO cell labeling and noninvasive MR monitoring of human tissue-engineered vascular grafts in vivo. FASEB J 2008; 22 (11) : 3888-3895.
88. Arifin DR, Long CM, Gilad AA, et al. Trimodal gadolinium-gold microcapsules containing pancreatic islet cells restore normoglycemia in diabetic mice and can be tracked by using US, CT, and positive-contrast MR imaging. Radiology 2011; 260 (3) : 790-798.
89. Barnett BP, Ruiz-Cabello J, Hota P, et al. Fluorocapsules for improved function, immunoprotection, and visualization of cellular therapeutics with MR, US, and CT imaging. Radiology 2011; 258 (1) : 182-191.
90. Chan KW, Liu G, Song X, et al. MRIdetectable pH nanosensors incorporated into hydrogels for in vivo sensing of transplanted-cell viability. Nat Mater 2013; 12 (3) : 268-275.
91. Krämer NA, Donker HC, Otto J, et al. A concept for magnetic resonance visualization of surgical textile implants. Invest Radiol 2010; 45 (8) : 477-483.
92. Luderer F, Begerow I, Schmidt W, et al. Enhanced visualization of biodegradable polymeric vascular scaffolds by incorporation of gold, silver and magnetite nanoparticles. J Biomater Appl 2013; 28 (2) : 219-231.
93. Perea H, Aigner J, Heverhagen JT, Hopfner U, Wintermantel E. Vascular tissue engineering with magnetic nanoparticles: Seeing deeper. J Tissue Eng Regen Med 2007; 1 (4) : 318-321.
94. Barnett BP, Arepally A, Karmarkar PV, et al. Magnetic resonance-guided, real-Time targeted delivery and imaging of magnetocapsules immunoprotecting pancreatic islet cells. Nat Med 2007; 13 (8) : 986-991.
95. Kiessling FM. Science to practice: Are theranostic agents with encapsulated cells the key for diabetes therapy? Radiology 2011; 260 (3) : 613-615.
96. Jayapaul J, Arns S, Lederle W, et al. Riboflavin carrier protein-Targeted fluorescent USPIO for the assessment of vascular metabolism in tumors. Biomaterials 2012; 33 (34) : 8822-8829.
97. Tassa C, Shaw SY, Weissleder R. Dextrancoated iron oxide nanoparticles: A versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Acc Chem Res 2011; 44 (10) : 842-852.
98. Fréchou M, Beray-Berthat V, Raynaud JS, et al. Detection of vascular cell adhesion molecule-1 expression with USPIO-enhanced molecular MRI in a mouse model of cerebral ischemia. Contrast Media Mol Imaging 2013; 8 (2) : 157-164.
99. Burtea C, Ballet S, Laurent S, et al. Development of a magnetic resonance imaging protocol for the characterization of atherosclerotic plaque by using vascular cell adhesion molecule-1 and apoptosis-Targeted ultrasmall superparamagnetic iron oxide derivatives. Arterioscler Thromb Vasc Biol 2012; 32 (6) : E36-e48.
100. Strijkers GJ, Kluza E, Van Tilborg GA, et al. Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis. Angiogenesis 2010; 13 (2) : 161-173.
101. Preda A, van Vliet M, Krestin GP, Brasch RC, van Dijke CF. Magnetic resonance macromolecular agents for monitoring tumor microvessels and angiogenesis inhibition. Invest Radiol 2006; 41 (3) : 325-331.
102. Arbab AS, Pandit SD, Anderson SA, et al. Magnetic resonance imaging and confocal microscopy studies of magnetically labeled endothelial progenitor cells trafficking to sites of tumor angiogenesis. Stem Cells 2006; 24 (3) : 671-678.
103. 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J 2007; 21 (8) : 1647-1654.
104. Hoehn M, Wiedermann D, Justicia C, et al. Cell tracking using magnetic resonance imaging. J Physiol 2007; 584 (Pt 1) : 25-30.
105. Hoehn M, Küstermann E, Blunk J, et al. Monitoring of implanted stem cell migration in vivo: A highly resolved in vivo magnetic resonance imaging investigation of experimental stroke in rat. Proc Natl Acad Sci U S A 2002; 99 (25) : 16267-16272.
106. Bulte JW, Douglas T, Witwer B, et al. Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol 2001; 19 (12) : 1141-1147.
107. Ahrens ET, Flores R, Xu H, Morel PA. In vivo imaging platform for tracking immunotherapeutic cells. Nat Biotechnol 2005; 23 (8) : 983-987.
108. Voura EB, Jaiswal JK, Mattoussi H, Simon SM. Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy. Nat Med 2004; 10 (9) : 993-998.
109. Zhang C, Jugold M, Woenne EC, et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res 2007; 67 (4) : 1555-1562.
110. Schmieder AH, Winter PM, Williams TA, et al. Molecular MR imaging of neovascular progression in the Vx2 tumor with avb3-Targeted paramagnetic nanoparticles. Radiology 2013; 268 (2) : 470-480.
111. Kim YH, Jeon J, Hong SH, et al. Tumor targeting and imaging using cyclic RGDPEGylated gold nanoparticle probes with directly conjugated iodine-125. Small 2011; 7 (14) : 2052-2060.
112. Kiessling F, Bzyl J, Fokong S, Siepmann M, Schmitz G, Palmowski M. Targeted ultrasound imaging of cancer: An emerging technology on its way to clinics. Curr Pharm Des 2012; 18 (15) : 2184-2199.
113. Bzyl J, Lederle W, Rix A, et al. Molecular and functional ultrasound imaging in differently aggressive breast cancer xenografts using two novel ultrasound contrast agents (BR55 and BR38). Eur Radiol 2011; 21 (9) : 1988-1995.
114. Tardy I, Pochon S, Theraulaz M, et al. Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55. Invest Radiol 2010; 45 (10) : 573-578.
115. Pysz MA, Foygel K, Rosenberg J, Gambhir SS, Schneider M, Willmann JK. Antiangiogenic cancer therapy: Monitoring with molecular US and a clinically translatable contrast agent (BR55). Radiology 2010; 256 (2) : 519-527.
116. Pochon S, Tardy I, Bussat P, et al. BR55: A lipopeptide-based VEGFR2-Targeted ultrasound contrast agent for molecular imaging of angiogenesis. Invest Radiol 2010; 45 (2) : 89-95.
117. Grouls C, Hatting M, Rix A, et al. Liver dysplasia: US molecular imaging with targeted contrast agent enables early assessment. Radiology 2013; 267 (2) : 487-495.
118. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004; 22 (8) : 969-976.
119. De la Zerda A, Zavaleta C, Keren S, et al. Carbon nanotubes as photoacoustic molecular imaging agents in living mice. Nat Nanotechnol 2008; 3 (9) : 557-562.
120. Kresse M, Wagner S, Pfefferer D, Lawaczeck R, Elste V, Semmler W. Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in vivo by using transferrin receptor pathways. Magn Reson Med 1998; 40 (2) : 236-242.
121. Reuveni T, Motiei M, Romman Z, Popovtzer A, Popovtzer R. Targeted gold nanoparticles enable molecular CT imaging of cancer: An in vivo study. Int J Nanomedicine 2011; 6: 2859-2864.
122. Li J, Chaudhary A, Chmura SJ, et al. A novel functional CT contrast agent for molecular imaging of cancer. Phys Med Biol 2010; 55 (15) : 4389-4397.
123. Ghann WE, Aras O, Fleiter T, Daniel MC. Syntheses and characterization of lisinopril-coated gold nanoparticles as highly stable targeted CT contrast agents in cardiovascular diseases. Langmuir 2012; 28 (28) : 10398-10408.
124. Lindner JR. Molecular imaging of myocardial and vascular disorders with ultrasound. JACC Cardiovasc Imaging 2010; 3 (2) : 204-211.
125. Kiessling F, Fokong S, Koczera P, Lederle W, Lammers T. Ultrasound microbubbles for molecular diagnosis, therapy, and theranostics. J Nucl Med 2012; 53 (3) : 345-348.
126. Oostendorp M, Douma K, Wagenaar A, et al. Molecular magnetic resonance imaging of myocardial angiogenesis after acute myocardial infarction. Circulation 2010; 121 (6) : 775-783.
127. Chung EY, Kim HM, Lee GH, et al. Design of deformable chitosan microspheres loaded with superparamagnetic iron oxide nanoparticles for embolotherapy detectable by magnetic resonance imaging. Carbohydr Polym 2012; 90 (4) : 1725-1731.
128. Bartling SH, Budjan J, Aviv H, et al. First multimodal embolization particles visible on x-ray/computed tomography and magnetic resonance imaging. Invest Radiol 2011; 46 (3) : 178-186.
129. Lewis AL, Dreher MR. Locoregional drug delivery using image-guided intra-Arterial drug eluting bead therapy. J Control Release 2012; 161 (2) : 338-350.
130. D'Arienzo M, Chiaramida P, Chiacchiararelli L, et al. 90Y PET-based dosimetry after selective internal radiotherapy treatments. Nucl Med Commun 2012; 33 (6) : 633-640.
131. Stone R, Willi T, Rosen Y, Mefford OT, Alexis F. Targeted magnetic hyperthermia. Ther Deliv 2011; 2 (6) : 815-838.
132. Harrington KJ, Mohammadtaghi S, Uster PS, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001; 7 (2) : 243-254.
133. Koukourakis MI, Koukouraki S, Giatromanolaki A, et al. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas: Rationale for combination with radiotherapy. Acta Oncol 2000; 39 (2) : 207-211.
134. Seymour LW, Ferry DR, Anderson D, et al. Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 2002; 20 (6) : 1668-1676.
135. Seymour LW, Ferry DR, Kerr DJ, et al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol 2009; 34 (6) : 1629-1636.
136. Sharma KV, Dreher MR, Tang Y, et al. Development of "imageable" beads for transcatheter embolotherapy. J Vasc Interv Radiol 2010; 21 (6) : 865-876.
137. Maier-Hauff K, Ulrich F, Nestler D, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol 2011; 103 (2) : 317-324.
138. Van De Wiele C, Maes A, Brugman E, et al. SIRT of liver metastases: Physiological and pathophysiological considerations. Eur J Nucl Med Mol Imaging 2012; 39 (10) : 1646-1655.
139. Wang X, Chen H, Zheng Y, et al. Aunanoparticle coated mesoporous silica nanocapsule-based multifunctional platform for ultrasound mediated imaging, cytoclasis and tumor ablation. Biomaterials 2013; 34 (8) : 2057-2068.
140. Niu D, Wang X, Li Y, et al. Facile synthesis of magnetite/perfluorocarbon co-loaded organic/inorganic hybrid vesicles for dualmodality ultrasound/magnetic resonance imaging and imaging-guided high-intensity focused ultrasound ablation. Adv Mater 2013; 25 (19) : 2686-2692.
141. Xu QC, Zhang Y, Tan MJ, et al. AnticAngptl4 Ab-conjugated N-TiO (2)/NaYF (4) : Yb, Tm nanocomposite for near infrared-Triggered drug release and enhanced targeted cancer cell ablation. Adv Healthc Mater 2012; 1 (4) : 470-474.
142. Shen H, You J, Zhang G, et al. Cooperative, nanoparticle-enabled thermal therapy of breast cancer. Adv Healthc Mater 2012; 1 (1) : 84-89.
143. Su Y, Wei X, Peng F, et al. Gold nanoparticles-decorated silicon nanowires as highly efficient near-infrared hyperthermia agents for cancer cells destruction. Nano Lett 2012; 12 (4) : 1845-1850.
144. Yang K, Feng L, Shi X, Liu Z. Nano-graphene in biomedicine: Theranostic applications. Chem Soc Rev 2013; 42 (2) : 530-547.
145. Chertok B, David AE, Yang VC. Brain tumor targeting of magnetic nanoparticles for potential drug delivery: Effect of administration route and magnetic field topography. J Control Release 2011; 155 (3) : 393-399.
146. David AE, Cole AJ, Chertok B, Park YS, Yang VC. A combined theoretical and in vitro modeling approach for predicting the magnetic capture and retention of magnetic nanoparticles in vivo. J Control Release 2011; 152 (1) : 67-75.
147. Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev 2010; 62 (11) : 1052-1063.
148. Lammers T, Kiessling F, Hennink WE, Storm G. Nanotheranostics and image-guided drug delivery: Current concepts and future directions. Mol Pharm 2010; 7 (6) : 1899-1912.
149. Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev 2010; 62 (11) : 1064-1079.
150. Kiessling F, Heilmann M, Lammers T, et al. Synthesis and characterization of HE-24.8: A polymeric contrast agent for magnetic resonance angiography. Bioconjug Chem 2006; 17 (1) : 42-51.
151. Lammers T, Subr V, Peschke P, et al. Image-guided and passively tumour-Targeted polymeric nanomedicines for radiochemotherapy. Br J Cancer 2008; 99 (6) : 900-910.
152. Kaittanis C, Shaffer TM, Ogirala A, et al. Environment-responsive nanophores for therapy and treatment monitoring via molecular MRI quenching. Nat Commun doi: 10.1038/ncomms4384. Published online March 4, 2014.
153. De Smet M, Heijman E, Langereis S, Hijnen NM, Grüll H. Magnetic resonance imaging of high intensity focused ultrasound mediated drug delivery from temperature-sensitive liposomes: An in vivo proof-of-concept study. J Control Release 2011; 150 (1) : 102-110.
154. Ranjan A, Jacobs GC, Woods DL, et al. Image-guided drug delivery with magnetic resonance guided high intensity focused ultrasound and temperature sensitive liposomes in a rabbit Vx2 tumor model. J Control Release 2012; 158 (3) : 487-494.
155. Grüll H, Langereis S. Hyperthermia-Triggered drug delivery from temperaturesensitive liposomes using MRI-guided high intensity focused ultrasound. J Control Release 2012; 161 (2) : 317-327.
156. Lammers T, Rizzo LY, Storm G, Kiessling F. Personalized nanomedicine. Clin Cancer Res 2012; 18 (18) : 4889-4894.
157. Lammers T. Smart drug delivery systems: Back to the future vs. clinical reality. Int J Pharm 2013; 454 (1) : 527-529.